spns2

Spns2-IN-1 is a potent Spns2 inhibitor, effectively impeding Spns2-dependent S1P transport with an IC50 value of 1.4±0.3 μM, crucial for modulating the immune response [1].

Spns2-IN-2 (compound 3a) is an inhibitor of SPNS2.

SLF1081851 is a Spns2 inhibitor. SLF1081851 inhibits S1P release with IC50 of 1.93 μM.

SLF80821178 is a potent and orally active inhibitor of sphingosine-1-phosphate transporter (Spns2). It inhibits S1P release in HeLa cells with an IC50 of 51 nM and has a half-life of 2.4 hours in mice.

SLF1081851 (hydrochloride), a Spns2 inhibitor, effectively inhibits S1P release with an IC50 value of 1.93 μM. This compound is instrumental in the development and functioning of the immune system [1].

SLB1122168, an inhibitor targeting the sphingosine-1-phosphate (S1P) transporter Spns2 (with an IC50 of 94 nM for the mouse transporter), selectively reduces circulating lymphocyte counts without altering plasma S1P concentrations in mice at a dosage of 10 mg/kg.

SLF1081851 (TFA) is a Spns2 inhibitor with an IC50 value of 1.93 μM for inhibiting S1P release, playing a key role in development and the immune system.

SLF80821178 hydrochloride is an orally active anticancer compound that effectively targets the inhibitory function of Spns2 (sphingosine-1-phosphate transporter) and can significantly reduce the release of sphingosine-1-phosphate (S1P) in HeLa cells. Has an IC50 value of 51 nM. Furthermore, SLF80821178 hydrochloride effectively reduced circulating lymphocyte levels in a mouse model without significant effects on plasma S1P levels.

SLB1122168 is a potent inhibitor of Spns2-mediated sphingosine-1-phosphate (S1P) release, exhibiting an IC50 value of 94 nM [1].